Contraindicated Combinations: Monoamine oxidase inhibitors [nonselective as well as selective A (moclobemide) and B (selegiline)], risk of "serotonin syndrome" (see Contraindications).
Inadvisable Combinations: Sympathomimetic Agents: Melitracen may potentiate the cardiovascular effects of adrenaline, ephedrine, isoprenaline, noradrenaline, phenylephrine and phenylpropanolamine (eg, as contained in local and general anaesthetics and nasal decongestants).
Adrenergic Neurone Blockers: Deanxit may counteract the antihypertensive effects of guanethidine, betanidine, reserpine, clonidine and methyldopa. It is advisable to review all antihypertensive therapy during treatment with tricyclic antidepressants.
Anticholinergic Agents: Tricyclic antidepressants may potentiate the effects of these drugs on the eye, central nervous system (CNS), bowel and bladder; concomitant use of these should be avoided due to an increased risk of paralytic ileus, hyperpyrexia.
Drugs Which May Increase the QT Interval: Increases in the QT interval related to antipsychotic treatment may be exacerbated by the co-administration of other drugs known to significantly increase the QT interval. Co-administration of such drugs should be avoided. Relevant classes include: Class Ia and III antiarrhythmics (eg, quinidine, amiodarone, sotalol, dofetilide); some antipsychotics (eg, thioridazine); some macrolides (eg, erythromycin); some antihistamine (eg, terfenadine, astemizole); some quinolone antibiotics (eg, gatifloxacin, moxifloxacin).
The list mentioned is not exhaustive and other individual drugs known to significantly increase QT interval (eg, cisapride, lithium) should be avoided.
Drugs known to cause electrolyte disturbances eg, thiazide diuretica (hypokalaemia) and drugs known to increase the plasma concentration of flupentixol should also be used with caution as they may increase the risk of QT prolongation and malignant arrhythmias (see Precautions).
Combinations Requiring Precautions for Use: Central Nervous System Depressants: Deanxit may enhance the effects of alcohol, barbiturates and other CNS depressants.
Lithium: Concomitant use of Deanxit and lithium increases the risk of neurotoxicity.
Levodopa: Deanxit may reduce the effect of levodopa and increase the risk of cardiac side effects.
Incompatibilities: Not applicable.